In brief: Cytopia, Visiomed
Wednesday, 27 April, 2005
Cytopia (ASX:CYT) has received ethics approval to begin a Phase I clinical trial of its anti-cancer drug CYT997 at at the Royal Brisbane and Women's Hospital. The trial will be conducted in association with the Queensland Institute of Medical Research and Q-Pharm. Cytopia chief scientific officer Andrew Wilks said that the 30-patient trial would be a non-blinded, dose escalation study in patients with various cancers and could take between nine and twelve months.
Visiomed has received an initial purchase order for approximately 1500 Funhaler asthma spacers from its Australian distributor, Cottman Australia, a subsidiary of Advance Healthcare Group Limited (ASX:AHG). The order will take up 100 per cent of the Visiomed's first production run.
Link between oestrogen and heart health found in women
Scientists found that oestrogen helps increase the ANXA1 protein, and when ANXA1 is missing, the...
Frequent nightmares accelerate aging, increase risk of death
Nghtmares independently predict faster biological aging and earlier mortality — even after...
Cardiac organoids bring hope for treating heart disease
Australian scientists have developed lab-grown, three-dimensional heart tissues known as cardiac...
